HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Concurrent paclitaxel/cisplatin with thoracic radiation in patients with stage IIIA/B non-small cell carcinoma of the lung.

Abstract
Nine patients with stage IIIB non-small cell lung cancer were entered into a phase II trial designed to determine the feasibility of giving a combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin concurrent with thoracic radiation. Paclitaxel was given as a 24-hour infusion (135 mg/m2) followed by cisplatin (75 mg/m2) every 4 weeks, for a total of four cycles. Thoracic radiation was given concurrently with the first two cycles of chemotherapy, for a total dose of 64.8 Gy over 6 weeks. Neutropenia and esophagitis were the most common toxicities, with 66% of patients experiencing grade 3 or 4 neutropenia and 55% experiencing grade 3 or 4 esophagitis. Grade 3 pulmonary toxicity developed in 33% of patients. All patients were able to receive the full dose of radiation, although half of the patients required some modification of the chemotherapy regimen. There was one complete response and four partial responses, yielding a 56% overall response rate. This study demonstrates that it is feasible to treat patients with stage IIIB non-small cell lung cancer with paclitaxel/cisplatin plus concurrent thoracic radiation, with a degree of toxicity comparable with that associated with a degree of toxicity comparable with that associated with other concurrent combined-modality regimens for this disease.
AuthorsS J Antonia, H Wagner, C Williams, M Alberts, D Hubbell, L Robinson, J Hilstro, J C Ruckdeschel
JournalSeminars in oncology (Semin Oncol) Vol. 22 Issue 4 Suppl 9 Pg. 34-7 (Aug 1995) ISSN: 0093-7754 [Print] United States
PMID7644926 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
Chemical References
  • Paclitaxel
  • Cisplatin
Topics
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, radiotherapy)
  • Cisplatin (administration & dosage, adverse effects)
  • Combined Modality Therapy
  • Esophagitis (etiology)
  • Feasibility Studies
  • Female
  • Humans
  • Infusions, Intravenous
  • Lung (drug effects, radiation effects)
  • Lung Neoplasms (drug therapy, radiotherapy)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neutropenia (etiology)
  • Paclitaxel (administration & dosage, adverse effects)
  • Radiotherapy (adverse effects)
  • Radiotherapy Dosage
  • Remission Induction
  • Thorax

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: